Cargando…

Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration

INTRODUCTION: Timely anti-vascular endothelial growth factor (VEGF) treatment is crucial for visual function in neovascular age-related macular degeneration (nAMD). The aim of this study was to assess the reasons for anti-VEGF treatment delay during the COVID-19 lockdown and its clinical impact in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zarranz-Ventura, Javier, Escobar-Barranco, José J., Gómez-Baldó, Laia, Gallego-Pinazo, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441892/ https://www.ncbi.nlm.nih.gov/pubmed/37400599 http://dx.doi.org/10.1007/s40123-023-00757-2

Ejemplares similares

Patient and retina specialists’ preferences in neovascular age-related macular degeneration treatment. A discrete choice experiment
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2021)

IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review
por: Chaudhary, Varun, et al.
Publicado: (2022)

Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment
por: Yeter, D.Y., et al.
Publicado: (2021)

Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration
por: Sobolewska, Bianka, et al.
Publicado: (2021)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2011)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations
por: Kodjikian, Laurent, et al.
Publicado: (2021)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Smoking and Age-Related Macular Degeneration: Review and Update
por: Velilla, Sara, et al.
Publicado: (2013)

Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration
por: Szegedi, Stephan, et al.
Publicado: (2022)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2022)

A Delphi Study to Detect Deficiencies and Propose Actions in Real Life Treatment of Neovascular Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2014)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration
por: Lin, Liang-Wei, et al.
Publicado: (2023)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration
por: Nassisi, Marco, et al.
Publicado: (2023)

Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
por: Mrejen, Sarah, et al.
Publicado: (2015)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2016)

Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy
por: Prea, Selwyn M., et al.
Publicado: (2015)

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
por: Wen, Joanne C., et al.
Publicado: (2017)

Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration
por: Mantel, Irmela, et al.
Publicado: (2019)

Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy
por: Cao, Xuan, et al.
Publicado: (2022)

Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration
por: Miyata, Manabu, et al.
Publicado: (2021)

OCT-Derived Radiomic Features Predict Anti–VEGF Response and Durability in Neovascular Age-Related Macular Degeneration
por: Kar, Sudeshna Sil, et al.
Publicado: (2022)

Suspension of Anti-VEGF Treatment Does Not Affect Expansion of RPE Atrophy in Neovascular Age-Related Macular Degeneration
por: Chujo, Shinichiro, et al.
Publicado: (2023)

Decrease in Anti-VEGF Injections After Post-injection Endophthalmitis in Patients With Neovascular Age-Related Macular Degeneration
por: Binczyk, Natalia M., et al.
Publicado: (2023)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Do Nutritional Supplements Have a Role in Age Macular Degeneration Prevention?
por: Pinazo-Durán, Maria D., et al.
Publicado: (2014)

Peripapillary and macular microvasculature in neovascular age-related macular degeneration in long-term and recently started anti-VEGF therapy versus healthy controls
por: Türksever, Cengiz, et al.
Publicado: (2023)

Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration
por: Riaz, Moeen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b1bphfmhk3c9gci6hemrmaq2d4